Candel Therapeutics (CADL) Enterprise Value (2020 - 2025)

Candel Therapeutics has disclosed Enterprise Value across 6 years of filings, most recently posting -$119.7 million for Q4 2025.

• Enterprise Value for Q4 2025 came in at -$119.7 million, down 16.64% year-over-year; the trailing twelve-month figure through Dec 2025 was -$119.7 million (down 16.64% YoY), and the FY2025 annual result was -$119.7 million, down 16.64% from the prior year.
• Enterprise Value came in at -$119.7 million for Q4 2025 at Candel Therapeutics, down from -$87.0 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$16.6 million in Q3 2024 to a low of -$119.7 million in Q4 2025.
• The 5-year median for Enterprise Value is -$77.2 million (2022), against an average of -$67.3 million.
• Across the five-year window, Enterprise Value soared 61.48% in 2024 and slumped 425.2% in 2025, its largest moves.
• Candel Therapeutics' Enterprise Value stood at -$82.6 million in 2021, then advanced by 15.23% to -$70.1 million in 2022, then jumped by 49.45% to -$35.4 million in 2023, then plunged by 189.88% to -$102.7 million in 2024, then slipped by 16.64% to -$119.7 million in 2025.
• The last three Enterprise Value figures came in at -$119.7 million (Q4 2025), -$87.0 million (Q3 2025), and -$100.7 million (Q2 2025), per Business Quant data.